2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. Inc. (MRK) based on the data provided.

**1. Return Rate Comparison:**

*   **MRK Overview:** Merck & Co. Inc. is a global pharmaceutical company.
*   **MRK Cumulative Return:** 22.93%
*   **S&P 500 (VOO) Cumulative Return:** 91.00%
*   **Divergence:** -68.08 (Relative Divergence: 23.8)

*   **Analysis:** MRK has significantly underperformed the S&P 500 over the period for which the cumulative returns were calculated. The divergence of -68.08% indicates a substantial gap in performance. The relative divergence of 23.8 suggests that the current divergence is near the lower end of its historical range of divergence.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2016-2018  | 24.0% | 14.7% | 21.0%  | 0.7  | 182.1  |
| 2017-2019  | 37.0% | 14.7% | 20.0%  | 0.7  | 216.8  |
| 2018-2020  | 13.0% | 19.3% | -8.0%  | 0.7  | 195.0  |
| 2019-2021  | 0.0%  | 19.3% | -43.0% | 0.6  | 191.4  |
| 2020-2022  | 14.0% | 16.3% | 16.0%  | 0.5  | 277.1  |
| 2021-2023  | 31.0% | 14.3% | 30.0%  | 0.3  | 272.3  |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3  | 248.5  |
| 2023-2025  | -24.0%| 39.0% | -86.0% | 0.3  | 262.9  |

*   **Analysis:**
    *   **CAGR (Compound Annual Growth Rate):** Varies significantly, with negative growth in the most recent periods.
    *   **MDD (Maximum Drawdown):** Fluctuates. The MDD is recently high, implying high risk/volatility.
    *   **Alpha:**  Generally positive in earlier periods, but strongly negative in recent years, suggesting underperformance relative to its benchmark. Alpha has decreased drastically in recent years.
    *   **Beta:** Consistently below 1, indicating lower volatility than the market. Beta is decreasing.
    *   **Cap (B):** Market capitalization shows an overall increase over time, even with some fluctuations.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 106.45
*   **Previous Close:** 105.26
*   **Change:** 1.13
*   **5-day SMA:** 106.23
*   **20-day SMA:** 102.01
*   **60-day SMA:** 94.48

*   **Analysis:**
    *   The stock price increased by 1.13 recently, suggesting a positive short-term movement.
    *   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This indicates an upward trend in the short-term, with the price rising above its recent averages.
    *   The positive change suggests that the stock experienced a rebound.

**3. Indicator Analysis:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 75.58
*   **PPO (Percentage Price Oscillator):** 0.0841
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2026-01-02)
*   **Recent (20 days) relative divergence change:** 2.0 (+)
*   **Expected Return (%):** -27.3%

*   **Analysis:**
    *   **MRI:** A value of 0.8 suggests that MRK is a medium-risk investment.
    *   **RSI:** A value of 75.58 indicates that the stock is overbought, which might suggest a potential pullback.
    *   **PPO:** The PPO value of 0.0841 indicates the magnitude of price change.
    *   **Hybrid Signal:** The signal recommends a buy position, indicating a positive outlook despite the high RSI, but that signal will use most cash to take that buy position.
    *   **Recent divergence change:** Suggests a short-term rise.
    *   **Expected Return:**  A negative expected return of -27.3% is concerning, indicating that long-term investment from this point may lead to underperformance compared to the S&P 500.

**4. Recent News & Significant Events:**

*   **Key Headlines:**
    *   Merck stock performance as markets open in 2026.
    *   Morgan Stanley increased its price target for Merck due to an improved biopharma outlook.
    *   Asset Management One Co. Ltd. Purchased Shares of Merck & Co.
    *   An article discusses the legitimacy of Merck stock's run.
    *   A Seeking Alpha article presents a framework for Merck's success.
    *   Quiver Quantitative noted a 3% drop in MRK stock on a specific day.

*   **Analysis:**  The news is mixed. Positive news includes an increased price target and institutional buying. Negative news includes a stock price drop and articles questioning the sustainability of the stock's performance. Overall sentiment may be mixed.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.90 (Buy)
*   **Opinions:** 26
*   **Target Price:** Average: 110.04, High: 139.00, Low: 83.00

*   **Analysis:** Analyst consensus is generally positive, with a "Buy" rating and an average target price slightly above the current price. However, the wide range between the high and low target prices indicates some uncertainty among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-11-05 | 2.32 | 17.28 B$   |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2025-11-05 | 1.25 | 16.66 B$   |

*   **Analysis:**
    *   EPS (Earnings Per Share) has fluctuated over the past year, showing higher values in the most recent quarters.
    *   Revenue has generally increased over the same period, indicating growth in sales.
    *   The higher EPS and revenue in recent quarters are positive signs.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.28B   | 77.69%        |
| 2025-06-30   | $15.81B   | 77.50%        |
| 2025-03-31   | $15.53B   | 77.98%        |
| 2024-12-31   | $15.62B   | 75.50%        |
| 2024-09-30   | $16.66B   | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $51.85B   | 11.16%  |
| 2025-06-30   | $48.99B   | 9.04%   |
| 2025-03-31   | $48.34B   | 10.51%  |
| 2024-12-31   | $46.31B   | 8.08%   |
| 2024-09-30   | $44.50B   | 7.09%   |

*   **Analysis:**
    *   **Revenue:** Generally increasing, indicating healthy sales growth.
    *   **Profit Margin:** Remains consistently high, suggesting strong profitability and efficient cost management.
    *   **Equity:** Increasing, indicating growth in the company's net worth.
    *   **ROE (Return on Equity):** Improving, demonstrating better returns for shareholders.

**7. Comprehensive Analysis (Summary):**

*   **Performance:** MRK has significantly underperformed the S&P 500 over the specified period. The negative Alpha values in recent years are concerning.
*   **Technical Indicators:** The RSI suggests the stock is overbought, while the moving averages indicate an upward trend.
*   **News:** The news flow presents a mixed picture, with positive analyst updates balanced by concerns about stock performance and short-term drops.
*   **Analyst Opinion:** The overall analyst consensus is "Buy," but the wide range in price targets indicates some uncertainty.
*   **Earnings & Financials:** Recent earnings and financial data show strong revenue growth, high profit margins, and increasing equity and ROE.
*   **Overall Assessment:** While the recent financial performance and analyst outlook are positive, the underperformance compared to the market and the negative expected return are red flags. Investors should weigh the strong fundamentals against the potential for continued underperformance. The Hybrid Signal recommends a buy position, but the negative Alpha suggests underperformance compared to its benchmark. This suggests caution in making investment decisions for this stock. The high RSI indicates that this stock could correct soon as it is overbought.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.